Scott N. Holden
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Angiogenesis and VEGF in Cancer, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab(2007)932 cited
- → Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer(2010)591 cited
- → Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer(2005)389 cited
- → Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?(2012)326 cited
- → Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab(2005)322 cited
- → Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors(2005)306 cited
- → Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer(2012)262 cited
- → Predicting benefit from anti-angiogenic agents in malignancy(2006)228 cited
- → Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development(2013)186 cited
- → Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors(2007)125 cited